Open AccessCurrent landscape of palliative radiotherapy for non-small-cell lung cancer
Author(s) -
Raphaël Jumeau,
Florent Vilotte,
André-Dante Durham,
Esat-Mahmut Ozsahin
Publication year - 2019
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2019.08.10
Subject(s) - medicine , lung cancer , sabr volatility model , radiation therapy , palliative care , immunotherapy , concomitant , oncology , stage (stratigraphy) , ablative case , radiosurgery , brachytherapy , chemotherapy , cancer , radiology , volatility (finance) , paleontology , stochastic volatility , nursing , financial economics , economics , biology
Radiotherapy (RT) is a cornerstone in the management of advanced stage III and stage IV non-small-cell lung cancer (NSCLC) patients. Despite international guidelines, clinical practice remains heterogeneous. Additionally, the advent of stereotactic ablative RT (SABR) and new systemic treatments such as immunotherapy have shaken up dogmas in the approach of these patients. This review will focus on palliative thoracic RT for NSCLC but will also discuss the role of stereotactic radiotherapy, endobronchial brachytherapy (EBB), the interest of concomitant treatments (chemotherapy and immunotherapy), and the role of RT in lung cancer emergencies with palliative intent.